SEC Form 4 · accession 0001104659-26-099222
PALVELLA THERAPEUTICS, INC. · PVLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathleen Goin
Officer — Chief Operating Officer
Period of report
Aug 19, 2026
Accepted (ET)
Aug 20, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001583648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 19, 2026 | M | 2,154 | $7.14 | A | 2,154 | D | |
| Common Stock | Aug 19, 2026 | M | 2,148 | $9.08 | A | 4,302 | D | |
| Common StockF2 | Aug 19, 2026 | S | 1,500 | $151.39 | D | 2,802 | D | |
| Common StockF3 | Aug 19, 2026 | S | 1,998 | $151.7979 | D | 804 | D | |
| Common StockF4 | Aug 19, 2026 | S | 400 | $152.9975 | D | 404 | D | |
| Common StockF5 | Aug 19, 2026 | S | 102 | $155.5898 | D | 302 | D | |
| Common Stock | Aug 19, 2026 | S | 302 | $156.77 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $7.14 | Aug 19, 2026 | M | 2,154 | D | — | Oct 29, 2029 | Common Stock | 2,154 | 4,319 | D |
| Stock Option (Right to Buy)F6 | $9.08 | Aug 19, 2026 | M | 2,148 | D | — | Oct 14, 2030 | Common Stock | 2,148 | 4,296 | D |
Explanation of responses
- F1The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.62 to $151.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.665 to $152.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.93 to $153.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.58 to $155.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F6The stock option is fully vested.